TY  - JOUR
AU  - Del Rio, Carmen
AU  - Ruiz-Pino, Francisco
AU  - Prados, Maria E
AU  - Fiebich, Bernd L
AU  - Tena-Sempere, Manuel
AU  - Muñoz, Eduardo
PY  - 2022
DO  - 10.3389/fphar.2022.981817
SN  - 1663-9812
UR  - http://hdl.handle.net/10668/20712
T2  - Frontiers in pharmacology
AB  - Cannabidiol (CBD) has been suggested as a potential therapy for inflammatory and fibrotic diseases. Cannabidiol was demonstrated to reduce alcohol-induced liver inflammation and steatosis but its specific activity on the fibrotic process was not...
LA  - en
PB  - Frontiers Research Foundation
KW  - COL1A2
KW  - Cannabidiol
KW  - Fibrosis
KW  - Non-alcoholic fatty liver disease
KW  - Systemic sclerosis
KW  - Cannabis
KW  - Interleukin-4
KW  - Immunochemistry
KW  - Scleroderma, Systemic
KW  - Skin Diseases
KW  - Collagen
KW  - Liver Cirrhosis
KW  - Inflammation
KW  - Fibroblasts
KW  - Macrophages
KW  - Transcription, Genetic
TI  - Cannabidiol markedly alleviates skin and liver fibrosis.
TY  - research article
VL  - 13
ER  -